Cargando…
Successful induction treatment of bullous pemphigoid using reslizumab: a case report
BACKGROUND: Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596938/ https://www.ncbi.nlm.nih.gov/pubmed/34784964 http://dx.doi.org/10.1186/s13223-021-00619-1 |
_version_ | 1784600500726923264 |
---|---|
author | Rhyou, Hyo-In Han, Song-Hee Nam, Young-Hee |
author_facet | Rhyou, Hyo-In Han, Song-Hee Nam, Young-Hee |
author_sort | Rhyou, Hyo-In |
collection | PubMed |
description | BACKGROUND: Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further elucidated in BP, and have been considered potential therapeutic targets. CASE PRESENTATIONS: A 67-year-old male presented with erythematous bullous eruption. The skin eruption was located on whole body, and suggested BP. Peripheral blood eosinophil count and total immunoglobulin E markedly elevated in initial laboratory findings. Topical and systemic steroid (methylprednisolone 2 mg/kg/day) treatment was started, and his skin symptoms worsened repeatedly, whenever systemic steroid were reduced. On admission day 29, reslizumab (anti-interleukin-5) 3.5 mg/kg was administered intravenously to the patients. The bullous skin lesion began to improve rapidly, and methylprednisolone (8 mg/day) was reduced without any worsening of symptoms during two doses of reslizumab. CONCLUSIONS: We report a case of successful treatment response to reslizumab administration in a patient with BP. Further studies are needed to confirm the role of anti-interleukin-5 as a treatment for BP in the future. |
format | Online Article Text |
id | pubmed-8596938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85969382021-11-17 Successful induction treatment of bullous pemphigoid using reslizumab: a case report Rhyou, Hyo-In Han, Song-Hee Nam, Young-Hee Allergy Asthma Clin Immunol Case Report BACKGROUND: Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further elucidated in BP, and have been considered potential therapeutic targets. CASE PRESENTATIONS: A 67-year-old male presented with erythematous bullous eruption. The skin eruption was located on whole body, and suggested BP. Peripheral blood eosinophil count and total immunoglobulin E markedly elevated in initial laboratory findings. Topical and systemic steroid (methylprednisolone 2 mg/kg/day) treatment was started, and his skin symptoms worsened repeatedly, whenever systemic steroid were reduced. On admission day 29, reslizumab (anti-interleukin-5) 3.5 mg/kg was administered intravenously to the patients. The bullous skin lesion began to improve rapidly, and methylprednisolone (8 mg/day) was reduced without any worsening of symptoms during two doses of reslizumab. CONCLUSIONS: We report a case of successful treatment response to reslizumab administration in a patient with BP. Further studies are needed to confirm the role of anti-interleukin-5 as a treatment for BP in the future. BioMed Central 2021-11-16 /pmc/articles/PMC8596938/ /pubmed/34784964 http://dx.doi.org/10.1186/s13223-021-00619-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Rhyou, Hyo-In Han, Song-Hee Nam, Young-Hee Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title | Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title_full | Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title_fullStr | Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title_full_unstemmed | Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title_short | Successful induction treatment of bullous pemphigoid using reslizumab: a case report |
title_sort | successful induction treatment of bullous pemphigoid using reslizumab: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596938/ https://www.ncbi.nlm.nih.gov/pubmed/34784964 http://dx.doi.org/10.1186/s13223-021-00619-1 |
work_keys_str_mv | AT rhyouhyoin successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport AT hansonghee successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport AT namyounghee successfulinductiontreatmentofbullouspemphigoidusingreslizumabacasereport |